Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging

Hannes Grünig; Alexander Maurer; Yannick Thali; Zsofia Kovacs; Klaus Strobel; Irene A Burger; Joachim Müller

doi:10.1007/s00259-021-05424-x

Focal unspecific bone uptake on [¹⁸F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging

Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4483-4494. doi: 10.1007/s00259-021-05424-x. Epub 2021 Jun 13.

Authors

Hannes Grünig¹, Alexander Maurer¹, Yannick Thali², Zsofia Kovacs³, Klaus Strobel², Irene A Burger^{4

5}, Joachim Müller³

Affiliations

¹ Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
² Department of Nuclear Medicine and Radiology, Cantonal Hospital Lucerne, Lucerne, Switzerland.
³ Department of Radiology and Nuclear Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
⁴ Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland. irene.burger@ksb.ch.
⁵ Department of Nuclear Medicine, Cantonal Hospital Baden, Baden, Switzerland. irene.burger@ksb.ch.

Abstract

Purpose: Improved logistics and availability led to a rapid increase in the use of [¹⁸F]-PSMA-1007 for prostate cancer PET imaging. Initial data suggests increased uptake in benign lesions compared to [⁶⁸ Ga]-PSMA-11, and clinical observations found increased unspecific bone uptake (UBU). We therefore investigate the frequency and characteristics of UBU in [¹⁸F]-PSMA-1007 PET.

Methods: We retrospectively analyzed [¹⁸F]-PSMA-1007 PET scans from four centers for the presence of UBU, defined as a focal mild-to-moderate uptake (SUV_max < 10.0) not obviously related to a benign or malignant cause. If present, up to three leading UBUs were quantified (SUV_max), localized, and correlated to clinical parameters, such as age, PSA, injected dose, Gleason score, tumor size (T1-T4), and type of PET scanner (analog vs. digital). Additionally, clinical and imaging follow-up results and therapeutic impact were evaluated.

Results: UBUs were identified in 179 out of 348 patients (51.4%). The most frequent localizations were ribs (57.5%) and pelvis (24.8%). The frequency of UBUs was not associated with PSA, Gleason score, tumor size, age, or the injected [¹⁸F]-PSMA-1007 dose. UBUs were significantly more frequent in images obtained with digital PET/CT scans (n = 74, 82%) than analog PET/CT scans (n = 221, 40.3%) (p = .0001) but not in digital PET/MR (n = 53, 51%) (p = .1599). In 80 out of 179 patients (44.7%), the interpretation of UBUs was critical for therapeutic management and therefore considered clinically relevant. For 65 UBUs, follow-ups were available: three biopsies, three radiotherapies with PSA follow-up, and 59 cases with imaging. After follow-up, UBUs were still considered unclear in 28 of 65 patients (43%), benign in 28 (43%), and malignant in nine (14%) patients.

Conclusion: UBUs occur in two-thirds of patients imaged with [¹⁸F]-PSMA-1007 PET/CT and are significantly more frequent on digital PET scanners than analog scanners. UBUs should be interpreted carefully to avoid over-staging.

Keywords: Bone metastasis; PET/CT; PET/MR; Restaging; Staging; [18F]-PSMA.

Publication types

Multicenter Study

MeSH terms

Edetic Acid
Humans
Male
Niacinamide / analogs & derivatives
Oligopeptides
Positron Emission Tomography Computed Tomography*
Positron-Emission Tomography
Prostatic Neoplasms* / diagnostic imaging
Retrospective Studies
Tomography, X-Ray Computed

Substances

Oligopeptides
PSMA-1007
Niacinamide
Edetic Acid